General Information of Drug (ID: DM2NA4K)

Drug Name
Ciclesonide Drug Info
Synonyms
Alvesco; Omnair; Omnaris; Osonase; Osonide; Alvesco HFA; Ciclesonide [INN]; Omnaris HFA; RPR 251526; Alvesco (TN); BTR-15; BTR-15K; BY-9010; BYK-20426; KS-1165; Omnaris (TN); Omniair (TN); TBN-15; B-9207-015; Ciclesonide (JAN/USAN/INN); (R)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with cyclohexanecarboxaldehyde, 21-isobutyrate
Therapeutic ClassAntiallergic Agents
Cross-matching ID
PubChem CID
6918155
ChEBI ID
CHEMBL2040682
CAS Number
CAS 126544-47-6
TTD Drug ID
D0K7HU
VARIDT Drug ID
DR01408
INTEDE Drug ID
DR0319

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name NES FDR q-val Tag % Leading Edge Genes
Oxidative phosphorylation 2.33 0.00e+0 93/133 (69.92%) COX5B;NDUFA6;NDUFA7;...
Complement and coagulation cascades 2.21 0.00e+0 76/85 (89.41%) C3;SERPINE1;F3;...
Drug metabolism 2.02 3.13e-3 78/151 (51.66%) MAOA;NAT1;ADH1B;...
Staphylococcus aureus infection 2.00 2.35e-3 72/95 (75.79%) C3;C1QB;C1QA;...
Sulfur metabolism 2.00 1.88e-3 9/10 (90%) TST;SQOR;MPST;...
Non-alcoholic fatty liver disease 1.97 3.13e-3 126/155 (81.29%) COX5B;NDUFA6;CYCS;...
Peroxisome 1.95 2.68e-3 72/82 (87.8%) IDH2;PEX11A;PXMP4;...
Ribosome 1.95 2.35e-3 113/158 (71.52%) MRPS16;RPS5;MRPL15;...
Mineral absorption 1.94 2.09e-3 48/60 (80%) MT1E;MT1M;MT1G;...
Nicotinate and nicotinamide metabolism 1.92 1.88e-3 25/35 (71.43%) NNMT;NAMPT;NMRK1;...
Phenylalanine metabolism 1.90 1.71e-3 14/17 (82.35%) MAOA;GOT1;GLYAT;...
Tyrosine metabolism 1.90 1.57e-3 30/36 (83.33%) MAOA;ADH1B;ADH5;...
Parkinson disease 1.87 2.89e-3 176/249 (70.68%) DUSP1;MAOA;BCL2L1;...
Metabolism of xenobiotics by cytochrome P450 1.80 1.21e-2 49/77 (63.64%) EPHX1;ADH1B;ADH5;...
Glycine, serine and threonine metabolism 1.80 1.13e-2 31/40 (77.5%) MAOA;CBS;BHMT;...
DNA replication 1.75 1.76e-2 34/36 (94.44%) RPA3;RNASEH2A;POLE2;...
Arachidonic acid metabolism 1.74 1.71e-2 48/61 (78.69%) PLAAT3;ALOX5;AKR1C3;...
Thermogenesis 1.73 2.04e-2 173/232 (74.57%) COX5B;RPS6KA2;NDUFA6;...
Fatty acid degradation 1.70 2.37e-2 40/43 (93.02%) ACAA2;ADH1B;ADH5;...
Huntington disease 1.70 2.68e-2 233/306 (76.14%) POLR2I;COX5B;NDUFA6;...
Arginine biosynthesis 1.69 2.77e-2 17/22 (77.27%) ASS1;GLUL;GOT1;...
p53 signaling pathway 1.66 3.59e-2 63/73 (86.3%) SERPINE1;GADD45B;GADD45G;...
N-Glycan biosynthesis 1.64 3.84e-2 38/50 (76%) ALG5;ST6GAL1;MAN1A1;...
Diabetic cardiomyopathy 1.62 4.89e-2 162/203 (79.8%) PDK4;COX5B;NDUFA6;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 3H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.04uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 24H